Download Brochure
Table of Content
Get a Price
April 2025
.webp)
Principal Consultant
Reviewed By
The global pelvic inflammatory disease treatment market size is calculated at US$ 3.52 in 2024, grew to US$ 3.65 billion in 2025, and is projected to reach around US$ 5.09 billion by 2034. The market is expanding at a CAGR of 3.75% between 2025 and 2034. Chronic pelvic pain, intra-abdominal infections, infertility, and ectopic pregnancy are common symptoms if PID is untreated. Thus, to reduce the impact of PID, timely diagnosis and suitable management, including the use of antibiotics, is necessary.
Inflammation of the upper genital tract due to an infection, particularly in women, is known as pelvic inflammatory disease (PID). The uterus, fallopian tubes, and/or ovaries are the main organs affected by this disease. A significant number of the population is affected globally by PID, impacting women’s reproductive health. Thus, early detection, along with the appropriate treatment options for PID, is driving the market. Similarly, with increasing awareness of PID, the demand for it is also rising.
The application of AI and machine learning in pelvic inflammatory diseases is still in development. At the same time, the introduction of AI in healthcare facilities has made it a lot easier to diagnose, monitor, and treat PID with high precision and efficiency. To offer personalized interventions, machine learning, predictive analytics, and real-time patient monitoring, along with AI-powered anti-inflammatory treatments, are being used. With the help of the data acquired by the AI, the inflammatory responses, tailor treatments, and drug efficacy can be optimized. This helps improve patient outcomes and decrease long-term complications. The integration of AI with anti-inflammatory protocols in specialized clinics and wellness centers is now driving medical tourism globally.
Increased Occurrence of Pelvic Inflammatory Disease
The increased occurrences of urinary tract infections, sexually transmitted diseases (STDs), and PCOS have led to a rise in the rate of PID as well as its complications, such as infertility. In certain cases, the PID may also be associated with the risk of stroke and ovarian cancer. Thus, the rise in awareness among women raises the demand for early diagnosis and treatment. As the incidence rate of PID increases, the women start preferring medical treatment to prevent further complications. This, in turn, causes a rise in the pelvic inflammatory disease treatment market.
In May 2024, according to the sexually transmitted infections monthly surveillance report, U.S. residents, that is, residents of St. Louis County, around 11 cases of syphilis, 175 cases of gonorrhea, and 503 cases of chlamydia were identified.
Lack of Early Diagnosis
Pelvic inflammatory disease (PID) is underdiagnosed globally, which may lead to complications if it is untreated. The symptoms of PID are usually mild and unclear, which can lead to misdiagnosis or delayed treatment. The diagnosis of PID is clinical, and there are no specific screening tests for PID in many healthcare facilities. The use of procedures like laparoscopy and endometrial biopsy may not be accessible to many patients. Thus, the PID remains undiagnosed.
Raising Awareness
Pelvic inflammatory disease treatment has several growth opportunities. The major opportunity responsible for the growth of the pelvic inflammatory disease treatment market is raising awareness. The increased awareness among patients about its signs and symptoms, along with the complications associated with it, is encouraging women to undergo regular diagnosis and treatment. The educational programs also play an important role for both healthcare providers and patients to undergo early diagnosis and treatment. Thus, as the awareness about PID grows, the demand for prevention and treatment options also increases.
By treatment type, the antibiotic therapy segment dominated the pelvic inflammatory disease treatment market in 2024. When the primary cause of PID is chlamydia or gonorrhea, the first line of treatment is always antibiotics. Antibiotics effectively target the bacteria responsible for PID, helping to control or eliminate the infection. Antibiotics are the preferred choice of treatment, as they are administered orally or intravenously, depending on the severity of the infection, to prevent complications. Thus, antibiotics provided a rapid and effective treatment option in the management of PID.
By treatment type, the surgery segment is predicted to show significant growth in the pelvic inflammatory disease treatment market during the forecast period. Surgery is usually used when the PID is associated with complications such as abscesses, chronic pelvic pain, etc. The type of surgery, particularly laparoscopic surgery, is significantly growing in the market because of its minimally invasive technique and small incisions as it recovers quickly with less scarring and fewer complications.
By route of administration type, the oral segment dominated the pelvic inflammatory disease treatment market in 2024. The oral route of administration was the preferred route of administration due to its improved patient compliance. Another reason for this was due to its non-invasive technique and convenience. This resulted in increased patient adherence to the treatment.
By route of administration type, the intravenous segment is expected to grow significantly during the forecast period. The use of intravenous treatments is increasing in case of rapid treatments and if a fast onset of action is required. It is also used when oral antibiotics become ineffective due to the resistance in certain patients.
By patient type, the adult women segment dominated the pelvic inflammatory disease treatment market in 2024. This was due to increased rates of STIs observed in the adult women. As the STIs were not timely diagnosed, this led to complications such as chronic pain, infertility, and ectopic pregnancy. This, in turn, increased the demand for early diagnosis and treatment options.
By patient type, adolescent girls segment is anticipated to grow significantly during the forecast period. Adolescent girls lack awareness about reproductive health and STIs, which is the major reason for the rising rates of PID in them. Thus, along with the increased demand for diagnosis and treatment, the demand for awareness programs or campaigns is also increasing.
By end-user type, the hospital segment dominated the pelvic inflammatory disease treatment market in 2024. To manage the complicated PID, the hospitals consisted of IV antibiotics and surgical equipment along with specialized staff. For patients suffering from severe complications, it also provided continuous monitoring and specialized treatments. Furthermore, advanced diagnosis, multidisciplinary care, and emergency services were also made available.
By end-user type, the specialty clinics segment is anticipated to show significant growth during the forecast period. Specialty clinics focus on women's reproductive health. These clinics offer expertise in diagnosing and treating PID. Patients prefer specialty clinics because they offer fast access to care and personalized treatment options. These clinics also provide preventive care and long-term management of PID, thus contributing to the market growth.
North America dominated the pelvic inflammatory disease treatment market in 2024. North America consists of well-developed healthcare facilities with advanced diagnostic and therapeutic technologies. It also showed high prevalence rates of STDs. Thus, all these factors, along with government support, resulted in the increased demand for pelvic inflammatory disease treatment.
The US shows a high incidence of PID. The PID caused by STIs such as chlamydia and gonorrhea is the major reason for this increased demand for PID treatments. The US also contributes to the research and development of new drugs, therapy, or other treatment options for PID. Furthermore, due to the strong regulatory framework, the new treatments are approved at fast rates, which introduces advanced PID treatment options.
Public health awareness is increasing regarding PID, due to which a high demand for early diagnosis and treatment is increasing rapidly in Canada. This causes healthcare facilities to enhance their treatment and diagnostic options. At the same time, different treatment and health campaigns also contribute to the rapid growth in the PID treatment market.
Asia Pacific is estimated to show the fastest growth in the market during the forecast period. This is due to the increasing population and high incidences of STIs causing PID. As the rate of infections increases, the demand for the treatment also increases. Thus, all these factors, along with the rising awareness, are contributing to the rapid growth of the market.
The large population plays an important role in PID increment. This drives the higher rates of STIs, which leads to PID and, thus, increased demand for the treatment of the same. The improved healthcare facilities provide advanced diagnostic and treatment options. Moreover, government funding for the development of new treatment options and rising awareness are driving the market.
India also shows increased rates of STIs due to the high population. Thus, to increase awareness, health campaigns about sexual health, reproductive health, and STI prevention are carried out. This leads to increased demand for early diagnosis and treatment of PID. Thus, the government and private sectors are investing in healthcare facilities to develop diagnostic and treatment options.
Europe is expected to grow significantly in the pelvic inflammatory disease treatment market during the forecast period. Europe provides a strong public health initiative focused on sexual health education and STI prevention. This causes increased awareness of PID, resulting in increased demand for early diagnostic options. It also consists of well-developed healthcare facilities which provide advanced diagnostic and treatment options for PID.
Germany consists of a well-developed healthcare infrastructure with specialized staff. This provides the patient with easy access to the diagnosis and treatment of PID. It also consists of well well-established pharmaceutical market improving the availability of treatment options. At the same time, various health programs and new treatment research are driving the market.
The increasing rates of STIs have increased the demand for PID treatments. Similarly, the increased awareness through the campaigns is contributing to early diagnosis and treatments. UK consists of advanced medical facilities that provide effective management of PID. All these factors are the reason for growing the market.
In March 2025, The senior author, Professor Catriona Bradshaw of the Melbourne Sexual Health Centre, while informing about bacterial vaginosis as an STD, announced that a lot of BV recurrence was observed in women due to reinfection from partners, which provided evidence that BV is, in fact, an STI (sexually transmitted infection).
By Treatment Type
By Route of Administration
By Patient Type
By End User
By Region
April 2025
April 2025
March 2025
March 2025
Book a Consultation